Most Cost-effective to Use Immunotherapy First in Melanoma Most Cost-effective to Use Immunotherapy First in Melanoma
Up-front immunotherapy is the most cost-effective option for treating newly diagnosed unresectable stage III or IV melanoma with unknown BRAF mutation status, concludes a modeling analysis.Medscape Medical News
Source: Medscape Dermatology Headlines - Category: Dermatology Tags: Hematology-Oncology News Source Type: news
More News: Cancer & Oncology | Dermatology | Hematology | Immunotherapy | Melanoma | Skin | Skin Cancer